JP2011505140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505140A5 JP2011505140A5 JP2010536117A JP2010536117A JP2011505140A5 JP 2011505140 A5 JP2011505140 A5 JP 2011505140A5 JP 2010536117 A JP2010536117 A JP 2010536117A JP 2010536117 A JP2010536117 A JP 2010536117A JP 2011505140 A5 JP2011505140 A5 JP 2011505140A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- polynucleotide
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 239000002157 polynucleotide Substances 0.000 claims 9
- 102000040430 polynucleotide Human genes 0.000 claims 9
- 108091033319 polynucleotide Proteins 0.000 claims 9
- 125000000539 amino acid group Chemical group 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000009123 Fibrin Human genes 0.000 claims 2
- 108010073385 Fibrin Proteins 0.000 claims 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 229950003499 fibrin Drugs 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 108010088842 Fibrinolysin Proteins 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 241001228709 Suruga Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108010015052 miniplasmin Proteins 0.000 claims 1
- 229940012957 plasmin Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99114807P | 2007-11-29 | 2007-11-29 | |
| US60/991,148 | 2007-11-29 | ||
| PCT/US2008/084645 WO2009073471A1 (en) | 2007-11-29 | 2008-11-25 | Recombinantly modified plasmin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011505140A JP2011505140A (ja) | 2011-02-24 |
| JP2011505140A5 true JP2011505140A5 (enExample) | 2012-01-19 |
| JP5539896B2 JP5539896B2 (ja) | 2014-07-02 |
Family
ID=40379999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010536117A Active JP5539896B2 (ja) | 2007-11-29 | 2008-11-25 | 組換え的に改変されたプラスミン |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8101394B2 (enExample) |
| EP (1) | EP2220221B1 (enExample) |
| JP (1) | JP5539896B2 (enExample) |
| KR (1) | KR101529743B1 (enExample) |
| CN (1) | CN101918548B (enExample) |
| AU (1) | AU2008331545B2 (enExample) |
| BR (1) | BRPI0819780B1 (enExample) |
| CA (1) | CA2707266C (enExample) |
| ES (1) | ES2534040T3 (enExample) |
| HU (1) | HUE024916T2 (enExample) |
| IL (1) | IL205936A (enExample) |
| MX (1) | MX2010005947A (enExample) |
| NZ (2) | NZ593837A (enExample) |
| PL (1) | PL2220221T3 (enExample) |
| PT (1) | PT2220221E (enExample) |
| WO (1) | WO2009073471A1 (enExample) |
| ZA (1) | ZA201003730B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5026254B2 (ja) | 2004-04-22 | 2012-09-12 | グリフオルス・セラピユーテイクス・インコーポレーテツド | 組換え的に改変されたプラスミン |
| WO2009073471A1 (en) | 2007-11-29 | 2009-06-11 | Talecris Biotherapeutics, Inc. | Recombinantly modified plasmin |
| UA103771C2 (ru) | 2008-06-04 | 2013-11-25 | Грифолз Терапьютикс Инк. | Стрептокиназа, активирующая плазмин, способ и набор для получения плазмина |
| HUE025670T2 (en) * | 2009-03-03 | 2016-04-28 | Grifols Therapeutics Inc | A method for producing plasminogen |
| EP2451835A1 (en) | 2009-07-10 | 2012-05-16 | ThromboGenics N.V. | Variants of plasminogen and plasmin |
| WO2011023805A1 (en) | 2009-08-28 | 2011-03-03 | Thrombogenics N.V. | Use of plasmin for the treatment of filtration failure after trabeculectomy |
| CN102121023B (zh) * | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| ES2583082T3 (es) | 2011-01-05 | 2016-09-19 | Thrombogenics N.V. | Variantes de plasminógeno y plasmina |
| WO2013024074A1 (en) | 2011-08-12 | 2013-02-21 | Thrombogenics N.V. | Plasminogen and plasmin variants |
| CN103205410B (zh) * | 2012-01-13 | 2018-03-06 | 蔺莹莹 | 重组微纤维蛋白溶酶及其制备方法和应用 |
| JP2016519081A (ja) | 2013-03-14 | 2016-06-30 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | ヘパリンと結合体化した抗トロンビンβに対するモノクローナル抗体 |
| DE102014112212A1 (de) * | 2014-08-26 | 2016-03-03 | Akesion Gmbh | Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen |
| FR3035120B1 (fr) * | 2015-04-15 | 2020-02-07 | Arcadophta | Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition |
| US11400142B2 (en) | 2015-12-18 | 2022-08-02 | Talengen International Limited | Treatment of diabetic nerve injury comprising administering plasminogen |
| DK3391902T5 (da) | 2015-12-18 | 2024-09-23 | Talengen Int Ltd | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati |
| JP2019500426A (ja) | 2015-12-18 | 2019-01-10 | タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ | 糖尿病網膜症を予防または治療するための方法 |
| CN108778307A (zh) | 2015-12-18 | 2018-11-09 | 泰伦基国际有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| CN110114080A (zh) | 2016-12-15 | 2019-08-09 | 泰伦基国际有限公司 | 一种预防和治疗皮肤纤维化的方法 |
| WO2018108161A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肥胖症的方法和药物 |
| CN110366425A (zh) * | 2016-12-15 | 2019-10-22 | 泰伦基国际有限公司 | 一种预防动脉粥样硬化及其并发症的方法 |
| JP7171572B2 (ja) * | 2016-12-15 | 2022-11-15 | タレンゲン インターナショナル リミテッド | 糖尿病を治療するための新しい方法 |
| EP3556385A4 (en) | 2016-12-15 | 2020-12-30 | Talengen International Limited | PROCESS FOR ALLEGING HEART DISEASE |
| CN108210910A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗系统性硬化症的药物及其用途 |
| TWI714862B (zh) | 2017-06-19 | 2021-01-01 | 大陸商深圳瑞健生命科學硏究院有限公司 | 一種調控glp-1/glp-1r的方法和藥物 |
| US11140020B1 (en) | 2018-03-01 | 2021-10-05 | Amazon Technologies, Inc. | Availability-enhancing gateways for network traffic in virtualized computing environments |
| US12226462B2 (en) | 2019-01-25 | 2025-02-18 | Council Of Scientific & Industrial Research | Fibrinolytic composition and method of its preparation |
| EP4140498A4 (en) * | 2020-05-11 | 2023-11-01 | Talengen International Limited | METHOD AND DRUGS FOR TREATING SPINAL MUSCLE ATROPHY |
| CN118308334B (zh) * | 2024-06-06 | 2024-10-08 | 深圳市卫光生物制品股份有限公司 | 一种重组人纤溶酶原及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4652639A (en) | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
| US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
| US4774087A (en) | 1987-08-14 | 1988-09-27 | Northwestern University | Micro-size fibrinolytic plasmin |
| US7253264B1 (en) | 1990-06-28 | 2007-08-07 | Sanofi-Arentideutschland GmbH | Immunoglobulin fusion proteins, their production and use |
| US6312893B1 (en) | 1996-01-23 | 2001-11-06 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
| US6613508B1 (en) | 1996-01-23 | 2003-09-02 | Qiagen Genomics, Inc. | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques |
| AU717435B2 (en) | 1996-01-23 | 2000-03-23 | Qiagen Genomics, Inc. | Methods and compositions for determining the sequence of nucleic acid molecules |
| JPH10158300A (ja) | 1996-11-28 | 1998-06-16 | Suzuki Motor Corp | 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法 |
| WO1999005322A1 (en) | 1997-07-22 | 1999-02-04 | Rapigene, Inc. | Computer method and system for correlating sequencing data by ms |
| IL140729A0 (en) | 1998-07-14 | 2002-02-10 | Bristol Myers Squibb Co | Lysine binding fragments of angiostatin, pharmaceutical compositions containing the same and processes for the preparation thereof |
| JP4577992B2 (ja) | 1998-09-29 | 2010-11-10 | リューベン・リサーチ・アンド・デベロップメント・ベー・ゼット・ウェー | 虚血性卒中の処置用の組成物を調製するための、α２抗プラスミンをインビボで減少する化合物の使用 |
| US6964764B2 (en) | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US6355243B1 (en) | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
| US6969515B2 (en) | 1999-11-13 | 2005-11-29 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| JP2004509609A (ja) | 2000-06-02 | 2004-04-02 | ブルー ヘロン バイオテクノロジー インコーポレイテッド | 合成二本鎖オリゴヌクレオチドの配列忠実度を改善するための方法 |
| AU2002218890A1 (en) * | 2000-12-21 | 2002-07-01 | Thromb-X N.V. | A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell |
| WO2003054232A2 (en) | 2001-12-13 | 2003-07-03 | Blue Heron Biotechnology, Inc. | Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins |
| DE10390418D2 (de) | 2002-02-06 | 2005-01-13 | N Zyme Biotec Gmbh | Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen |
| US7776026B2 (en) | 2002-02-06 | 2010-08-17 | Nuvue Technologies, Inc. | Method for vitreous liquefaction |
| GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
| JP5026254B2 (ja) * | 2004-04-22 | 2012-09-12 | グリフオルス・セラピユーテイクス・インコーポレーテツド | 組換え的に改変されたプラスミン |
| WO2007047874A2 (en) * | 2005-10-20 | 2007-04-26 | Talecris Biotherapeutics, Inc. | Recombinantly modified plasmin |
| WO2009073471A1 (en) | 2007-11-29 | 2009-06-11 | Talecris Biotherapeutics, Inc. | Recombinantly modified plasmin |
-
2008
- 2008-11-25 WO PCT/US2008/084645 patent/WO2009073471A1/en not_active Ceased
- 2008-11-25 MX MX2010005947A patent/MX2010005947A/es active IP Right Grant
- 2008-11-25 AU AU2008331545A patent/AU2008331545B2/en active Active
- 2008-11-25 EP EP08857923.0A patent/EP2220221B1/en active Active
- 2008-11-25 JP JP2010536117A patent/JP5539896B2/ja active Active
- 2008-11-25 HU HUE08857923A patent/HUE024916T2/en unknown
- 2008-11-25 US US12/744,376 patent/US8101394B2/en active Active
- 2008-11-25 NZ NZ593837A patent/NZ593837A/xx not_active IP Right Cessation
- 2008-11-25 NZ NZ585715A patent/NZ585715A/en not_active IP Right Cessation
- 2008-11-25 BR BRPI0819780-6A patent/BRPI0819780B1/pt not_active IP Right Cessation
- 2008-11-25 CN CN2008801232704A patent/CN101918548B/zh active Active
- 2008-11-25 PL PL08857923T patent/PL2220221T3/pl unknown
- 2008-11-25 KR KR1020107014243A patent/KR101529743B1/ko not_active Expired - Fee Related
- 2008-11-25 PT PT88579230T patent/PT2220221E/pt unknown
- 2008-11-25 ES ES08857923.0T patent/ES2534040T3/es active Active
- 2008-11-25 CA CA2707266A patent/CA2707266C/en active Active
-
2010
- 2010-05-24 IL IL205936A patent/IL205936A/en active IP Right Grant
- 2010-05-25 ZA ZA2010/03730A patent/ZA201003730B/en unknown
-
2011
- 2011-11-22 US US13/302,322 patent/US8182808B2/en active Active
-
2012
- 2012-05-03 US US13/463,437 patent/US8512980B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011505140A5 (enExample) | ||
| JP2009268467A5 (enExample) | ||
| EA201001881A1 (ru) | Пролинспецифичная протеаза из penicillium chrysogenum | |
| CA2563675A1 (en) | Recombinantly modified plasmin | |
| EA200901430A1 (ru) | Варианты фермента аспарагиназы и их применение | |
| JP2012532601A5 (enExample) | ||
| JP2018537099A5 (enExample) | ||
| EP1350843A3 (en) | Alkaline cellulase variants | |
| NZ595496A (en) | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them | |
| JP2012525836A5 (enExample) | ||
| IL205936A (en) | Polynucleotide encoding a polypeptide having a single curling site at the homologous n-terminus to a human plasminogen ringing site, an activation site and a serine protease site at the homologous c-terminal end to parallel regions in human plasminogen, the polypeptide and cod encoding the polypeptide | |
| WO2013182910A3 (en) | Transcription activator-like effector (tale) fusion protein | |
| JP2013519365A5 (enExample) | ||
| EP2470559A4 (en) | COAGULATION FACTOR IX COMPOSITIONS AND METHODS OF MAKING AND USING THEM | |
| WO2006073839A3 (en) | Acid fungal proteases | |
| JP2006149395A5 (enExample) | ||
| NZ593833A (en) | Extended recombinant polypeptides and compositions comprising same | |
| WO2005007867A3 (en) | Thermostable amylase polypeptides, nucleic acids encoding those polypeptides and uses thereof | |
| ATE400656T1 (de) | Mini-dystrophin nukleinsäure- und peptidsequenzen | |
| RU2011130932A (ru) | Композиции и способы модулирования гемостаза | |
| JP2014525439A5 (enExample) | ||
| RU2011154363A (ru) | Комбинации клад rrgb пневмококков | |
| JP2008536479A5 (enExample) | ||
| JP2008545393A5 (enExample) | ||
| WO2007113336A3 (de) | Funktionale expression von triacylglycerol-lipasen |